Pat Donnelly, Pharmaceutical Services CEO, Joins Linden Capital Partners as Operating Partner

Pat Donnelly, Pharmaceutical Services CEO, Joins Linden Capital Partners as Operating Partner

January 11, 2016

CHICAGO, Illinois (January 11, 2016) – Linden Capital Partners, a Chicago-based private equity firm with $1.3 billion of assets under management and focused exclusively on healthcare, today announced the addition of Patrick K. Donnelly as Operating Partner. Mr. Donnelly will partner with Linden to identify and acquire platform businesses in the outsourced pharmaceutical services space. Mr. Donnelly, who has more than 35 years of experience, was most recently Chairman and Chief Executive Officer of Aptiv Solutions, a global pharmaceutical development services business which sold to ICON (NASDAQ:ICLR) in May 2014. Prior to this, Pat served as President, Chief Executive Officer, and was one of the founders of PRA International (now PRA Health Sciences, NASDAQ:PRAH). He was instrumental in building PRA over twelve years from a small regional contract research organization to a global leader in the industry. 

“We are thrilled to partner with Pat and have had early success with our investment in Chesapeake IRB,” said Linden Principal Michael Farah. “Pat’s insights into Chesapeake’s business and conviction in its growth enabled us to prevail in a competitive process. His wealth of relevant industry experience positions Linden to continue to actively pursue investment opportunities across the pharmaceutical services subsector.” 

“Through my work with Linden in evaluating multiple opportunities, I have come to appreciate not only their rigor and depth throughout the due diligence process, but also the competitive advantage that working with a healthcare-exclusive fund brings,” commented Mr. Donnelly. “I am excited to partner with the entire Linden team as we pursue additional platform investments within the pharmaceutical services sector.” 

Before joining PRA International, Pat served as President of Virginia Capital LP and Vedcorp, LLC, two affiliated venture capital firms located in Richmond, Virginia. He spent eight years with BancBoston Capital. Mr. Donnelly received his M.B.A. from Pennsylvania State University in 1984 and received his BS from the University of Missouri in 1980. He currently serves as Chairman of Linden portfolio company, Chesapeake IRB, and is also a board director at MedGenesis Therapeutix, Phase 5 LLC, Celerion, and Rediscovery Life Sciences. 

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm with $1.3 billion in assets under management and focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare.